Eisai

News

First data with subcutaneous Leqembi, and other CTAD news

Eisai and Biogen have reported data showing that a subcutaneous formulation of its Alzheimer’s disease therapy Leqembi matched the current intravenous version at clearing

News

Leqembi approved in Japan, its first ex-US market

Eisai and Biogen now have their second regulatory approval for anti-amyloid therapy Leqembi – in Japan – as a treatment for slowing the progression of Alzheimer’s disease.

Views & Analysis

Dr. Lynn Kramer and Shobha Dhadda at DPHARM 2023 in Boston

How AI-powered adaptive design helped Eisai launch Leqembi

At DPHARM 2023 in Boston, Eisai insiders described the Bayesian design of Leqembi's phase 2 trial.

News

Eisai launches digital dementia specialist company

Eisai has been steadily building up expertise in the use of digital health systems to support people with dementia but has now gone one step further – launching a dedicate

News

Donanemab data an “important advance” in Alzheimer’s

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also

News

Uptake of Leqembi for Alzheimer’s may be slow

Full FDA approval of Eisai and Biogen’s Alzheimer’s disease therapy Leqembi may have unlocked the door to a broader rollout of the drug and potentially blockbuster sales,

First data with subcutaneous Leqembi, and other CTAD news

Leqembi approved in Japan, its first ex-US market

How AI-powered adaptive design helped Eisai launch Leqembi

Eisai launches digital dementia specialist company

Donanemab data an “important advance” in Alzheimer’s

Uptake of Leqembi for Alzheimer’s may be slow

LSX2026: On a therapeutic vision for ocular disease, with Al...

Using AI-driven synthetic personas to take your insights fur...

Eisai

Editor's Picks